Immuno-oncology programs
GPCRs constitute strategic targets mediating immunosuppression. The company exploits its expertise in the field to move forward small molecule and antibody based-assets toward the clinic.
Immuno-oncology
M1069
A2aR/A2bR antagonist
![Merck is one of Domain Therapeutics’s partners](https://www.domaintherapeutics.com/wp-content/uploads/2020/03/merck-1-e1637145445707.png)
DT-9081
EP4 receptor antagonist
![](https://www.domaintherapeutics.com/wp-content/uploads/2024/01/LOGO-DOMAIN.png)
DT-7012
Anti-CCR8 antibody
![](https://www.domaintherapeutics.com/wp-content/uploads/2024/01/LOGO-DOMAIN.png)
DT-9045
PAR2 antagonist
![](https://www.domaintherapeutics.com/wp-content/uploads/2024/01/LOGO-DOMAIN.png)
Undisclosed GPCR targets
![](https://www.domaintherapeutics.com/wp-content/uploads/2024/01/LOGO-DOMAIN.png)